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In the present case the patient was admit-
ted to the neurosurgical intensive care unit 
unconscious, GCS 3, and  presenting a 
dilated pupil. The admission CT showed 
a subdural mass with severe midline shift.
The biomarker S100B is used frequently 
in our NICU to monitor comatose patients 
and in this case the level was significantly 
increased. Although the CT findings indi-
cated that the patient was suffering from 
a chronic subdural hematoma, it later on 
was found to harbor metastatic growth 
from an initially unknown recurrence of a 
malignant melanoma.
Patients suffering from malignant mel-
anomas might present “false” high S100B 
levels after traumatic brain injury which has 
to be considered when there seems to be a 
discrepancy between clinical findings and 
the serum level of S100B.
The title was chosen because of the ini-
tial confusion concerning CT findings and 
neurology, and is kept to illustrate the com-
plexity of this case.
In the article, as is proposed by the 
authors Gelabert-González, Aran-Echabe, 
and Serramito-García, we never suggest that 
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We recently published the paper; “Case 
Report: Extreme Levels of Serum S100B 
in a Patient with Chronic Subdural 
Hematoma” (Persson et al., 2012), in 
Frontiers in Neurology. It was a case 
report concerning a patient with a sub-
dural mass, neurological deterioration, 
and unusually high S100B levels in serum. 
Further clinical examination proved that 
the patient was suffering from a malig-
nant melanoma.
We fully agree with Drs Gelabert-
González, Aran-Echabe, and Serramito-
Garcíain their manuscript “S-100 B 
protein and chronic subdural hematoma” 
that patients presenting chronic subdural 
hematomas do not normally benefit from 
biomarker (S100B and NSE) monitoring 
(Gelabert-González et al., 2013).
S100B is an important marker for chronic 
subdural hematoma. Instead we highlight 
the potential influence of other, non-glial 
sources of S100B that could affect diagnosis 
and clinical decision-making of patients in 
the neurointensive care unit.
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